Can a selective serotonin reuptake inhibitor act as a glutamatergic modulator?

Detalhes bibliográficos
Autor(a) principal: Frizzo, Marcos Emilio dos Santos
Data de Publicação: 2017
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFRGS
Texto Completo: http://hdl.handle.net/10183/169147
Resumo: Sertraline (Zoloft) and fluoxetine (Prozac) are selective serotonin reuptake inhibitors whose antidepressant mechanism of action is classically attributed to an elevation of the extracellular levels of serotonin in the synaptic cleft. However, the biological effects of these drugs seem to be more complex than their traditionally described mechanism of action. Among their actions is the inhibition of different types of Naþ and Kþ channels, as well as of glutamate uptake activity. The clearance of extracellular glutamate is essential to maintain the central nervous system within physiological conditions, and this excitatory neurotransmitter is removed from the synaptic cleft by astrocyte transporters. This transport depends upon a hyperpolarized membrane potential in astrocytes that is mainly maintained by Kir4.1 Kþ channels. The impairment of the Kir4.1 channel activity reduces driving force for the glutamate transporter, resulting in an accumulation of extracellular glutamate. It has been shown that sertraline and fluoxetine inhibit Kir4.1 Kþ channels. Recently, we demonstrated that sertraline reduces glutamate uptake in human platelets, which contain a high-affinity Naþ-dependent glutamate uptake system, with kinetic and pharmacological properties similar to astrocytes in the central nervous system. Considering these similarities between human platelets and astrocytes, one might ask if sertraline could potentially reduce glutamate clearance in the synaptic cleft and consequently modulate glutamatergic transmission. This possibility merits investigation, since it may provide additional information regarding the mechanism of action and perhaps the side effects of these antidepressants.
id UFRGS-2_a9e65532649d9bf09c32e1034373c887
oai_identifier_str oai:www.lume.ufrgs.br:10183/169147
network_acronym_str UFRGS-2
network_name_str Repositório Institucional da UFRGS
repository_id_str
spelling Frizzo, Marcos Emilio dos Santos2017-10-06T02:29:49Z20170011-393Xhttp://hdl.handle.net/10183/169147001048169Sertraline (Zoloft) and fluoxetine (Prozac) are selective serotonin reuptake inhibitors whose antidepressant mechanism of action is classically attributed to an elevation of the extracellular levels of serotonin in the synaptic cleft. However, the biological effects of these drugs seem to be more complex than their traditionally described mechanism of action. Among their actions is the inhibition of different types of Naþ and Kþ channels, as well as of glutamate uptake activity. The clearance of extracellular glutamate is essential to maintain the central nervous system within physiological conditions, and this excitatory neurotransmitter is removed from the synaptic cleft by astrocyte transporters. This transport depends upon a hyperpolarized membrane potential in astrocytes that is mainly maintained by Kir4.1 Kþ channels. The impairment of the Kir4.1 channel activity reduces driving force for the glutamate transporter, resulting in an accumulation of extracellular glutamate. It has been shown that sertraline and fluoxetine inhibit Kir4.1 Kþ channels. Recently, we demonstrated that sertraline reduces glutamate uptake in human platelets, which contain a high-affinity Naþ-dependent glutamate uptake system, with kinetic and pharmacological properties similar to astrocytes in the central nervous system. Considering these similarities between human platelets and astrocytes, one might ask if sertraline could potentially reduce glutamate clearance in the synaptic cleft and consequently modulate glutamatergic transmission. This possibility merits investigation, since it may provide additional information regarding the mechanism of action and perhaps the side effects of these antidepressants.application/pdfengCurrent Therapeutic Research: clinican and experimental. New York, NY. Vol. 87, (2017), p. 9-12SerotoninaReceptor NMDAAntidepressivosGlutamate modulatorZoloftProzacKir4.1 potassium channelsSertralineFluoxetineCan a selective serotonin reuptake inhibitor act as a glutamatergic modulator?Estrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSORIGINAL001048169.pdf001048169.pdfTexto completo (inglês)application/pdf241204http://www.lume.ufrgs.br/bitstream/10183/169147/1/001048169.pdf70e58bbfed7ef2e9df594b3f4e5c04b9MD51TEXT001048169.pdf.txt001048169.pdf.txtExtracted Texttext/plain26752http://www.lume.ufrgs.br/bitstream/10183/169147/2/001048169.pdf.txta8779099761372f3db5b530f013a2969MD52THUMBNAIL001048169.pdf.jpg001048169.pdf.jpgGenerated Thumbnailimage/jpeg2040http://www.lume.ufrgs.br/bitstream/10183/169147/3/001048169.pdf.jpg548eba31ebd77da922f7314ace6c5d1bMD5310183/1691472018-10-29 08:34:52.365oai:www.lume.ufrgs.br:10183/169147Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2018-10-29T11:34:52Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false
dc.title.pt_BR.fl_str_mv Can a selective serotonin reuptake inhibitor act as a glutamatergic modulator?
title Can a selective serotonin reuptake inhibitor act as a glutamatergic modulator?
spellingShingle Can a selective serotonin reuptake inhibitor act as a glutamatergic modulator?
Frizzo, Marcos Emilio dos Santos
Serotonina
Receptor NMDA
Antidepressivos
Glutamate modulator
Zoloft
Prozac
Kir4.1 potassium channels
Sertraline
Fluoxetine
title_short Can a selective serotonin reuptake inhibitor act as a glutamatergic modulator?
title_full Can a selective serotonin reuptake inhibitor act as a glutamatergic modulator?
title_fullStr Can a selective serotonin reuptake inhibitor act as a glutamatergic modulator?
title_full_unstemmed Can a selective serotonin reuptake inhibitor act as a glutamatergic modulator?
title_sort Can a selective serotonin reuptake inhibitor act as a glutamatergic modulator?
author Frizzo, Marcos Emilio dos Santos
author_facet Frizzo, Marcos Emilio dos Santos
author_role author
dc.contributor.author.fl_str_mv Frizzo, Marcos Emilio dos Santos
dc.subject.por.fl_str_mv Serotonina
Receptor NMDA
Antidepressivos
topic Serotonina
Receptor NMDA
Antidepressivos
Glutamate modulator
Zoloft
Prozac
Kir4.1 potassium channels
Sertraline
Fluoxetine
dc.subject.eng.fl_str_mv Glutamate modulator
Zoloft
Prozac
Kir4.1 potassium channels
Sertraline
Fluoxetine
description Sertraline (Zoloft) and fluoxetine (Prozac) are selective serotonin reuptake inhibitors whose antidepressant mechanism of action is classically attributed to an elevation of the extracellular levels of serotonin in the synaptic cleft. However, the biological effects of these drugs seem to be more complex than their traditionally described mechanism of action. Among their actions is the inhibition of different types of Naþ and Kþ channels, as well as of glutamate uptake activity. The clearance of extracellular glutamate is essential to maintain the central nervous system within physiological conditions, and this excitatory neurotransmitter is removed from the synaptic cleft by astrocyte transporters. This transport depends upon a hyperpolarized membrane potential in astrocytes that is mainly maintained by Kir4.1 Kþ channels. The impairment of the Kir4.1 channel activity reduces driving force for the glutamate transporter, resulting in an accumulation of extracellular glutamate. It has been shown that sertraline and fluoxetine inhibit Kir4.1 Kþ channels. Recently, we demonstrated that sertraline reduces glutamate uptake in human platelets, which contain a high-affinity Naþ-dependent glutamate uptake system, with kinetic and pharmacological properties similar to astrocytes in the central nervous system. Considering these similarities between human platelets and astrocytes, one might ask if sertraline could potentially reduce glutamate clearance in the synaptic cleft and consequently modulate glutamatergic transmission. This possibility merits investigation, since it may provide additional information regarding the mechanism of action and perhaps the side effects of these antidepressants.
publishDate 2017
dc.date.accessioned.fl_str_mv 2017-10-06T02:29:49Z
dc.date.issued.fl_str_mv 2017
dc.type.driver.fl_str_mv Estrangeiro
info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10183/169147
dc.identifier.issn.pt_BR.fl_str_mv 0011-393X
dc.identifier.nrb.pt_BR.fl_str_mv 001048169
identifier_str_mv 0011-393X
001048169
url http://hdl.handle.net/10183/169147
dc.language.iso.fl_str_mv eng
language eng
dc.relation.ispartof.pt_BR.fl_str_mv Current Therapeutic Research: clinican and experimental. New York, NY. Vol. 87, (2017), p. 9-12
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFRGS
instname:Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
instname_str Universidade Federal do Rio Grande do Sul (UFRGS)
instacron_str UFRGS
institution UFRGS
reponame_str Repositório Institucional da UFRGS
collection Repositório Institucional da UFRGS
bitstream.url.fl_str_mv http://www.lume.ufrgs.br/bitstream/10183/169147/1/001048169.pdf
http://www.lume.ufrgs.br/bitstream/10183/169147/2/001048169.pdf.txt
http://www.lume.ufrgs.br/bitstream/10183/169147/3/001048169.pdf.jpg
bitstream.checksum.fl_str_mv 70e58bbfed7ef2e9df594b3f4e5c04b9
a8779099761372f3db5b530f013a2969
548eba31ebd77da922f7314ace6c5d1b
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)
repository.mail.fl_str_mv
_version_ 1801224930312847360